title: Pharmacokinetics and Disposition of the Thiouracil Derivative PF-06282999, an Orally Bioavailable, Irreversible Inactivator of Myeloperoxidase Enzyme, Across Animals and Humans.
abstract: The thiouracil derivative PF-06282999 [2-(6-(5-chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide] is an irreversible inactivator of myeloperoxidase and is currently in clinical trials for the potential treatment of cardiovascular diseases. Concerns over idiosyncratic toxicity arising from bioactivation of the thiouracil motif to reactive species in the liver have been largely mitigated through the physicochemical (molecular weight, lipophilicity, and topological polar surface area) characteristics of PF-06282999, which generally favor elimination via nonmetabolic routes. To test this hypothesis, pharmacokinetics and disposition studies were initiated with PF-06282999 using animals and in vitro assays, with the ultimate goal of predicting human pharmacokinetics and elimination mechanisms. Consistent with its physicochemical properties, PF-06282999 was resistant to metabolic turnover from liver microsomes and hepatocytes from animals and humans and was devoid of cytochrome P450 inhibition. In vitro transport studies suggested moderate intestinal permeability and minimal transporter-mediated hepatobiliary disposition. PF-06282999 demonstrated moderate plasma protein binding across all of the species. Pharmacokinetics in preclinical species characterized by low to moderate plasma clearances, good oral bioavailability at 3- to 5-mg/kg doses, and renal clearance as the projected major clearance mechanism in humans. Human pharmacokinetic predictions using single-species scaling of dog and/or monkey pharmacokinetics were consistent with the parameters observed in the first-in-human study, conducted in healthy volunteers at a dose range of 20-200 mg PF-06282999. In summary, disposition characteristics of PF-06282999 were relatively similar across preclinical species and humans, with renal excretion of the unchanged parent emerging as the principal clearance mechanism in humans, which was anticipated based on its physicochemical properties and supported by preclinical studies.
authors.affiliation: Pfizer Inc., Cambridge, Massachusetts (J.Q.D., A.S.K.); and Pfizer Inc., Groton, Connecticut (M.V.V., A.W., T.R., L.D., B.F., S.G.T., K.S.).
authors.forename: Jennifer Q
authors.initials: JQ
authors.lastname: Dong
authors.affiliation: Pfizer Inc., Cambridge, Massachusetts (J.Q.D., A.S.K.); and Pfizer Inc., Groton, Connecticut (M.V.V., A.W., T.R., L.D., B.F., S.G.T., K.S.).
authors.forename: Manthena V
authors.initials: MV
authors.lastname: Varma
authors.affiliation: Pfizer Inc., Cambridge, Massachusetts (J.Q.D., A.S.K.); and Pfizer Inc., Groton, Connecticut (M.V.V., A.W., T.R., L.D., B.F., S.G.T., K.S.).
authors.forename: Angela
authors.initials: A
authors.lastname: Wolford
authors.affiliation: Pfizer Inc., Cambridge, Massachusetts (J.Q.D., A.S.K.); and Pfizer Inc., Groton, Connecticut (M.V.V., A.W., T.R., L.D., B.F., S.G.T., K.S.).
authors.forename: Tim
authors.initials: T
authors.lastname: Ryder
authors.affiliation: Pfizer Inc., Cambridge, Massachusetts (J.Q.D., A.S.K.); and Pfizer Inc., Groton, Connecticut (M.V.V., A.W., T.R., L.D., B.F., S.G.T., K.S.).
authors.forename: Li
authors.initials: L
authors.lastname: Di
authors.affiliation: Pfizer Inc., Cambridge, Massachusetts (J.Q.D., A.S.K.); and Pfizer Inc., Groton, Connecticut (M.V.V., A.W., T.R., L.D., B.F., S.G.T., K.S.).
authors.forename: Bo
authors.initials: B
authors.lastname: Feng
authors.affiliation: Pfizer Inc., Cambridge, Massachusetts (J.Q.D., A.S.K.); and Pfizer Inc., Groton, Connecticut (M.V.V., A.W., T.R., L.D., B.F., S.G.T., K.S.).
authors.forename: Steven G
authors.initials: SG
authors.lastname: Terra
authors.affiliation: Pfizer Inc., Cambridge, Massachusetts (J.Q.D., A.S.K.); and Pfizer Inc., Groton, Connecticut (M.V.V., A.W., T.R., L.D., B.F., S.G.T., K.S.).
authors.forename: Kazuko
authors.initials: K
authors.lastname: Sagawa
authors.affiliation: Pfizer Inc., Cambridge, Massachusetts (J.Q.D., A.S.K.); and Pfizer Inc., Groton, Connecticut (M.V.V., A.W., T.R., L.D., B.F., S.G.T., K.S.) amit.kalgutkar@pfizer.com.
authors.forename: Amit S
authors.initials: AS
authors.lastname: Kalgutkar
mesh_terms: D000081:Acetamides / Q000493:pharmacokinetics*; D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D018938:Caco-2 Cells; D065607:Cytochrome P-450 Enzyme Inhibitors / Q000378:metabolism; D004285:Dogs; D004353:Drug Evaluation, Preclinical / Q000379:methods; D005260:Female; D057809:HEK293 Cells; D000882:Haplorhini; D022781:Hepatocytes / Q000378:metabolism; D006801:Humans; D007408:Intestinal Absorption / Q000502:physiology; D008297:Male; D051379:Mice; D008862:Microsomes, Liver / Q000378:metabolism; D009195:Peroxidase / Q000378:metabolism; D011485:Protein Binding; D011744:Pyrimidinones / Q000493:pharmacokinetics*; D051381:Rats; D017208:Rats, Wistar; D013889:Thiouracil / Q000493:pharmacokinetics*
chemical_list: D000081:Acetamides; D065607:Cytochrome P-450 Enzyme Inhibitors; D011744:Pyrimidinones; D013889:Thiouracil; D009195:Peroxidase; C000605149:2-(6-(5-chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide